Status:
TERMINATED
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Lead Sponsor:
University of Chicago
Conditions:
Acute Decompensated Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute deco...
Detailed Description
The exact mechanism of cardiovascular benefit from SGLT2i continues to be the source of further research. The investigators hypothesize that heart failure patients with acute decompensated heart failu...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- Heart Failure Reduced ejection fraction (HFrEF) of 40 or less
- Estimated glomerular filtration rate (eGFR) \> 30milliliters(ml)/minute(min)/1.73 meter(m)2
- Admitted to CCU by advanced heart failure service for decompensated heart failure requiring continuous hemodynamic monitoring with a pulmonary artery catheter
Exclusion
- Diagnosis of type 1 diabetes mellitus
- eGFR \< 30ml/min/1.73m2
- age \< 18 years old
- Jehovah's witnesses
- Diagnosis of group 1 pulmonary arterial hypertension
- Insulin requirement above standard low dose sliding scale
- Patients with a history of diabetic ketoacidosis (DKA)
- Allergies to SGLT2i medications
- History of intolerance to SGLT2i medications
- Patients listed for cardiac transplantation or on mechanical support
- Pregnant or breastfeeding
Key Trial Info
Start Date :
May 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 23 2023
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05346653
Start Date
May 22 2023
End Date
May 23 2023
Last Update
September 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637